Soran Handrean, Adam Safwaan, Mohammad Jamal B, Ho Jan H, Schofield Jonathan D, Kwok See, Siahmansur Tarza, Liu Yifen, Syed Akheel A, Dhage Shaishav S, Stefanutti Claudia, Donn Rachelle, Malik Rayaz A, Banach Maciej, Durrington Paul N
Cardiovascular Research Group, Faculty of Biology, Medicine & Health, University of Manchester, UK.
Cardiovascular Trials Unit, University Department of Medicine, Manchester University NHS Foundation Trust, Manchester, UK.
Arch Med Sci. 2018 Jan;14(1):1-21. doi: 10.5114/aoms.2018.72238. Epub 2017 Dec 19.
Hypercholesterolaemia is amongst the most common conditions encountered in the medical profession. It remains one of the key modifiable cardiovascular risk factors and there have been recent advances in the risk stratification methods and treatment options available. In this review, we provide a background into hypercholesterolaemia for non-specialists and consider the merits of the different risk assessment tools available. We also provide detailed considerations as to: i) when to start treatment, ii) what targets to aim for and iii) the role of low density lipoprotein cholesterol.
高胆固醇血症是医疗行业中最常见的病症之一。它仍然是主要的可改变心血管危险因素之一,并且在风险分层方法和可用治疗选择方面最近有了进展。在本综述中,我们为非专业人士提供高胆固醇血症的背景知识,并考虑现有不同风险评估工具的优点。我们还详细考虑了以下方面:i)何时开始治疗,ii)目标值是多少,以及iii)低密度脂蛋白胆固醇的作用。